Resume

• 2006

  Ph.D.

  Board Certified in Nuclear Medical Physics by the American Board of Science in Nuclear Medicine

  Nuclear Engineering (Radiological Engineering)

  University of Tennessee-Knoxville

• 2003

  M.S.

  Thesis project consisted of an automated segmentation routine for use in cancer staging.

  Medical Imaging Physics

• 1999

  B.S.

  Senior research project consisted of one year study in muon detection. Developed portable 4 panel coincidence detection system for use in various teaching and physics experiments. With this system it was possible to measure muon flux

  muon lifetime

  muon speed

  and the quantum efficiency of each of the detector panels in use.

  Physics

  Member of the University of Tennesse Pride of the Southland Marching Band - 1st Trumpet 2 years

  Nuclear Physics and Instrumentation

  American Board of Science in Nuclear Medicine

• Dustin R Osborne

  Dustin R Osborne of The University of Tennessee Medical Center at Knoxville

  Knoxville with expertise in Medical Physics

  Molecular Physics

  Nuclear Engineering is on ResearchGate. Read 31 publications

  and contact Dustin R Osborne on ResearchGate

  the professional network for scientists.

  Research Gate - Dustin Osborne

  Project Management

  Healthcare

  Biomedical Engineering

  Data Analysis

  Medical Imaging

  Statistics

  Digital Imaging

  Process Improvement

  Data Mining

  Medical Devices

  Clinical Research

  Analysis

  Molecular Imaging

  Research

  Program Management

  Product Management

  Physics

  Technical Writing

  Management

  Market Research

  Guidance for Methods Descriptions Used in Preclinical Imaging Papers

  Wynne Schiffer

  Joseph D. Kalen

  Amy LeBlanc

  Guidance for Methods Descriptions Used in Preclinical Imaging Papers

  Dual Isotope SPECT Imaging of I-123 ad I-125

  Stephen Kennel

  GATE Validation of Standard Dual Energy Corrections in Small Animal SPECT-CT

  Melissa Neveu

  Mumtaz Syed

  Quantitative and qualitative comparison of continuous bed motion and traditional step and shoot PET/CT

  Dynamic molecular imaging provides bio-kinetic data that is used to characterize novel radiolabeled tracers for the detection of disease. Amyloidosis is a rare protein misfolding disease that can affect many organs. It is characterized by extracellular deposits composed principally of fibrillar proteins and hypersulfated proteoglycans. We have previously described a peptide

  p5

  which binds preferentially to amyloid deposits in a murine model of reactive (AA) amyloidosis. We have determined the whole body distribution of amyloid by molecular imaging techniques using radioiodinated p5. The loss of radioiodide from imaging probes due to enzymatic reaction has plagued the use of radioiodinated peptides and antibodies. Therefore

  we studied iodine-124-labeled p5 by using dynamic PET imaging of both amyloid-laden and healthy mice to assess the rates of amyloid binding

  the relevance of dehalogenation and the fate of the radiolabeled peptide. Rates of blood pool clearance

  tissue accumulation and dehalogenation of the peptide were estimated from the images. Comparisons of these properties between the amyloid-laden and healthy mice provided kinetic profiles whose differences may prove to be indicative of the disease state. Additionally

  we performed longitudinal SPECT/CT imaging with iodine-125-labeled p5 up to 72h post injection to determine the stability of the radioiodinated peptide when bound to the extracellular amyloid. Our data show that amyloid-associated peptide

  in contrast to the unbound peptide

  is resistant to dehalogenation resulting in enhanced amyloid-specific imaging. These data further support the utility of this peptide for detecting amyloidosis and monitoring potential therapeutic strategies in patients.

  Dynamic PET and SPECT imaging with radioiodinated

  amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation.

  Introduction: Cardiac amyloidosis is a rare condition characterized by the deposition of well-structured protein fibrils

  proteoglycans

  and serum proteins as amyloid. Recent work has shown that it may be possible to use 18F-Florbetapir to image cardiac amyloidosis. Current methods for assessment include invasive biopsy techniques. This work enhances foundational work by Dorbala et al. by developing a routine imaging and analysis protocol using 18F-Florbetapir for cardiac amyloid assessment.\n\nMethods: Eleven patients

  three healthy controls and eight myloid positive patients

  were imaged using 18F-Florbetapir to assess cardiac amyloid burden. Four of the patients were also imaged using 82Rb-Chloride to evaluate possible 18F-Florbetapir retention because of reduced myocardial blood flow. Quantitative methods using modeling

  SUVs and SUV ratios were used to define a new streamlined clinical imaging protocol that could be used routinely and provide patient stratification.\n\nResults: Quantitative analysis of 18F-Florbetapir cardiac amyloid data were compiled from a 20-min listmode protocol with data histogrammed into two static images at 0–5

  10–15

  or 15–20 min. Data analysis indicated the use of SUVs or ratios of SUVs calculated from regions draw in the septal wall were adequate in identification of all healthy controls from amyloid positive patients in this small cohort. Additionally

  we found that it may be possible to use this method to differentiate patients suffering from AL vs. TTR amyloid.\n\nConclusion: This work builds on the seminal work by Dorbala et al. by describing a short 18F-Florbetapir imaging protocol that is suitable for routine clinical use and uses a simple method for quantitative analysis of cardiac amyloid disease.

  A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using 18F-Florbetapir

  Shelley Acuff

  Ted T Chang

  Mark McKinney

  Alexander S Pasciak

  Frontiers in Oncology

  Radioembolization and the Dynamic Role of (90)Y PET/CT

  Multi-modality imaging provides coregistered PET-CT and SPECT-CT images; however such multi-modality workflows usually consist of sequential scans from the individual imaging components for each modality. This typical workflow may result in long scan times limiting throughput of the imaging system. Conversely

  acquiring multi-modality data simultaneously may improve correlation and registration of images

  improve temporal alignment of the acquired data

  increase imaging throughput

  and benefit the scanned subject by minimizing time under anesthetic. In this work

  we demonstrate the feasibility and procedure for modifying a commercially available preclinical SPECT-CT platform to enable simultaneous SPECT-CT acquisition. We also evaluate the performance of simultaneous SPECT-CT tomographic imaging with this modified system. Performance was accessed using a 57Co source and image quality was evaluated with phantoms in a series of simultaneous SPECT-CT scans.\n\nThis work is dedicated to Derek Austin who passed away during the final development of this paper

  Feasibility and Initial Performance of Simultaneous SPECT-CT Imaging Using a Commercial Multi-modality Preclinical Imaging System

  Amy K. LeBlanc

  Gina D. Galyon

  Emily B. Martin

  Stephen J. Kennel

  Murthy Akula

  Federica Morandi

  Josh Rowe

  Veterinary Radiology and Ultrasound

  WHOLE-BODY BIODISTRIBUTION OF 3'-DEOXY-3'-[18 F]FLUOROTHYMIDINE (18 FLT) IN HEALTHY ADULT CATS.

  Sanghyeb Lee

  Molecular Imaging

  http://molecularimaging.deckerpublishing.com/index.php/article/development-and-validation-of-a-complete-gate-model-of-the-siemens-inveon-trimodal-imaging-platform

  Development and Validation of a Complete GATE Model of the Siemens Inveon Trimodal Imaging Platform

  Amy K LeBlanc

  Jill Narak

  Federica Morandi

  Lindsay Williams

  American Journal of Veterinary Research

  Kinetic analysis of 2-([(18)F]fluoro)-2-deoxy-d-glucose uptake in brains of anesthetized healthy dogs.

  Patrick Barlow

  Shelley Acuff

  Journal of Nuclear Medicine Technology

  Reduction of Patient Anxiety in PET/CT Imaging by Improving Communication Between Patient and Technologist

  tina richey

  Background: Dose continues to be an area of concern in preclinical imaging studies

  especially for those imaging disease progression in longitudinal studies. To our knowledge

  this work is the first to characterize and assess dose from the Inveon CT imaging platform using nanoDot dosimeters. This work is also the first to characterize a new low-dose configuration available for this platform. Methodology/Principle Findings: nanoDot dosimeters from Landauer

  Inc. were surgically implanted into 15 wild type mice. Two nanoDots were placed in each animal: 1 just under the skin behind the spine and the other located centrally within the abdomen. A manufacturer-recommended CT protocol was created with 1 projection per degree of rotation acquired over 360 degrees. For best comparison of the low dose and standard configurations

  noise characteristics of the reconstructed images were used to match the acquisition protocol parameters. Results for all dose measurements showed the average dose delivered to the abdomen to be 13.8 cGy ± 0.74 and 0.97 cGy ±0.05 for standard and low dose configurations respectively. Skin measurements of dose averaged 15.99 cGy ± 0.72 and 1.18 cGy ± 0.06. For both groups

  the standard deviation to mean was less than 5.6%. The maximum dose received for the abdomen was 15.12 cGy and 0.97 cGy while the maximum dose for the skin was 17.3 cGy and 1.32 cGy. Control dosimeters were used for each group to validate that no unwanted additional radiation was present to bias the results. Conclusions/Significance: This study shows that the Inveon CT platform is suitable for imaging mice both for single and longitudinal studies. Use of low-dose detector hardware results in significant reductions in dose to subjects with a >12x (90%) reduction in delivered dose. Installation of this hardware on another in vivo microCT platform resulted in dose reductions of over 9x (89%).

  Characterization of X-ray Dose in Murine Animals Using microCT

  a New Low-Dose Detector and nanoDot Dosimeters

  Dustin

  Society of Nuclear Medicine and Molecular Imaging

  Siemens Medical Solutions

  Quantum Computing

  Cendant

  University of Tennessee

  University of Tennessee

  Knoxville Holiday Spectacular

  Cendant

  Knoxville Holiday Spectacular was founded as a charitable organization that worked to organize a holiday entertainment program for which all of the proceeds were given to local Knoxville charities. The peak of this program occurred in December 2003 when we organized the first official series of performances. The program was a one night only event consisting of the Knoxville Jazz Orchestra

  several local children's choirs

  Faith Promise Church Choir (notable for their highly publicized performance at the Music Mansion in Pigeon Forge) and a local brass quartet consisting of members of the Pride of the Southland Marching Band at the University of Tennessee.

  Knoxville Holiday Spectacular

  Owner/Founder/Operator

  Owner and Founder of Quantum Computing: This company works in home networking

  computer hardware repair and replacement

  virus and spyware removal and PC sales and consulting.

  Quantum Computing

  Coach/Trainer

  Cendant

  Applications Support Specialist

  Siemens Medical Solutions

  Graduate Research Assistant

  University of Tennessee

  Director

  Clinical Research

  Director of clinical research for the Molecular Imaging & Translational Research Program in the Department of Radiology

  University of Tennessee

  Workforce Management

  Cendant

  Associate Professor

  University of Tennessee

  University of Tennessee

  Knoxville

  TN

  Assistant Professor

  Radiology and the Institute for Biomedical Engineering

  Assistant Professor

  University of Tennessee

  Siemens Medical Solutions

  Knoxville

  TN

  Serve as the senior technical sales support engineer for Siemens Preclinical products. I also serve as an advanced back up resource for the Preclinical applications group. Our group supports the sales functions of all Preclinical offerings both nationally and internationally. We are responsible for tracking trends of the group

  generating quotes

  developing proposals. We provide technical support for our sales team and work closely with them to ensure that the systems we sell are configured to best suit the needs of the customer.

  Technical Sales Support Engineer

  Cendant

  Chair

  CMIIT Preclinical Task Force

  Society of Nuclear Medicine and Molecular Imaging

  Reservation Service Supervisor

  Cendant

  Siemens Medical Solutions

  knoxville

  tn

  Responsible for development of the Inveon Research Workplace software. This software is the primary visualization and analysis package purchased with the Inveon product line of preclinical imaging systems.

  IRW Product Manager

  University of Tennessee